Details of the Drug

General Information of Drug (ID: DM4YMIS)

Drug Name
Aldesleukin
Synonyms Proleukin (TN)
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [1]
Childhood myelodysplastic syndrome N.A. Approved [2]
Cutaneous melanoma 2C30 Approved [3]
Desmoplastic small round cell tumor N.A. Approved [2]
Leukemia N.A. Approved [1]
Lung cancer 2C25.0 Approved [4]
Renal cell carcinoma 2C90 Approved [5]
Non-hodgkin lymphoma 2B33.5 Phase 2 [5]
Colon cancer 2B90.Z Investigative [6]
Gastric cancer 2B72 Investigative [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Sequence
MAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCL
EEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLN
RWITFCQSIISTLT
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 13 - 85 minutes [7]
Vd
The volume of distribution (Vd) of drug is 0.18 L/kg []
Cross-matching ID
DrugBank ID
DB00041
TTD ID
D05PUD
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-2 (IL2) TTF89GD IL2_HUMAN Modulator [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute myelogenous leukaemia
ICD Disease Classification 2A41
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-2 (IL2) DTT IL2 5.88E-01 0.13 0.59
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Aldesleukin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Everolimus DM8X2EH Moderate Decreased metabolism of Aldesleukin caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [9]
Coadministration of a Drug Treating the Disease Different from Aldesleukin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [10]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Thioguanine. Acute myeloid leukaemia [2A60] [11]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Aldesleukin and Oliceridine. Acute pain [MG31] [12]
Chlorzoxazone DMCYVDT Moderate Additive CNS depression effects by the combination of Aldesleukin and Chlorzoxazone. Acute pain [MG31] [12]
Mepyramine DMB4SFH Moderate Additive CNS depression effects by the combination of Aldesleukin and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [13]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Aldesleukin and Inotersen. Amyloidosis [5D00] [14]
Marinol DM70IK5 Moderate Additive CNS depression effects by the combination of Aldesleukin and Marinol. Anorexia nervosa [6B80] [12]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [15]
Lorazepam DM84ZXF Moderate Additive CNS depression effects by the combination of Aldesleukin and Lorazepam. Anxiety disorder [6B00-6B0Z] [12]
Butalbital DM9J04X Moderate Additive CNS depression effects by the combination of Aldesleukin and Butalbital. Anxiety disorder [6B00-6B0Z] [12]
Buspirone DMBS632 Moderate Additive CNS depression effects by the combination of Aldesleukin and Buspirone. Anxiety disorder [6B00-6B0Z] [12]
Clorazepate DMC3JST Moderate Additive CNS depression effects by the combination of Aldesleukin and Clorazepate. Anxiety disorder [6B00-6B0Z] [13]
Alprazolam DMC7XDN Moderate Additive CNS depression effects by the combination of Aldesleukin and Alprazolam. Anxiety disorder [6B00-6B0Z] [12]
Methylphenobarbital DMDSWAG Moderate Additive CNS depression effects by the combination of Aldesleukin and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [13]
Hydroxyzine DMF8Y74 Moderate Additive CNS depression effects by the combination of Aldesleukin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [12]
Halazepam DMPFWO6 Moderate Additive CNS depression effects by the combination of Aldesleukin and Halazepam. Anxiety disorder [6B00-6B0Z] [12]
Chlordiazepoxide DMTN5XI Moderate Additive CNS depression effects by the combination of Aldesleukin and Chlordiazepoxide. Anxiety disorder [6B00-6B0Z] [12]
Chlormezanone DMTWUXR Moderate Additive CNS depression effects by the combination of Aldesleukin and Chlormezanone. Anxiety disorder [6B00-6B0Z] [12]
Clobazam - Lundbeck DMW1OQ0 Moderate Additive CNS depression effects by the combination of Aldesleukin and Clobazam - Lundbeck. Anxiety disorder [6B00-6B0Z] [12]
Oxazepam DMXNZM4 Moderate Additive CNS depression effects by the combination of Aldesleukin and Oxazepam. Anxiety disorder [6B00-6B0Z] [12]
Promazine DMZAL7W Moderate Additive CNS depression effects by the combination of Aldesleukin and Promazine. Appearance/behaviour symptom [MB23] [12]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Aldesleukin and Roflumilast. Asthma [CA23] [14]
Desipramine DMT2FDC Moderate Additive CNS depression effects by the combination of Aldesleukin and Desipramine. Attention deficit hyperactivity disorder [6A05] [12]
Ofloxacin DM0VQN3 Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [16]
Ciprofloxacin XR DM2NLS9 Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [16]
Trovafloxacin DM6AN32 Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [16]
Sparfloxacin DMB4HCT Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [16]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Aldesleukin and Linezolid. Bacterial infection [1A00-1C4Z] [17]
Gemifloxacin DMHT34O Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [16]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [16]
ABT-492 DMJFD2I Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [16]
Levofloxacin DMS60RB Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [16]
Moxifloxacin DMU8V4S Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Moxifloxacin. Bacterial infection [1A00-1C4Z] [16]
Lomefloxacin DMVRH9C Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [16]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Aldesleukin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [18]
Grepafloxacin DMGLX0T Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Grepafloxacin. Bronchitis [CA20] [16]
Secobarbital DM14RF5 Moderate Additive CNS depression effects by the combination of Aldesleukin and Secobarbital. Chronic insomnia [7A00] [12]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Aldesleukin and Dihydrocodeine. Chronic pain [MG30] [13]
Morphine DMRMS0L Moderate Additive CNS depression effects by the combination of Aldesleukin and Morphine. Chronic pain [MG30] [12]
Methohexital DM7YMIT Moderate Additive CNS depression effects by the combination of Aldesleukin and Methohexital. Corneal disease [9A76-9A78] [12]
Thiopental DMGP8AX Moderate Additive CNS depression effects by the combination of Aldesleukin and Thiopental. Corneal disease [9A76-9A78] [12]
Alfentanil DMVO0UB Moderate Additive CNS depression effects by the combination of Aldesleukin and Alfentanil. Corneal disease [9A76-9A78] [12]
Remifentanil DMZTXCH Moderate Additive CNS depression effects by the combination of Aldesleukin and Remifentanil. Corneal disease [9A76-9A78] [12]
Methadone DMTW6IU Moderate Additive CNS depression effects by the combination of Aldesleukin and Methadone. Cough [MD12] [12]
Cidofovir DMA13GD Major Increased risk of nephrotoxicity by the combination of Aldesleukin and Cidofovir. Cytomegaloviral disease [1D82] [19]
Sertraline DM0FB1J Moderate Additive CNS depression effects by the combination of Aldesleukin and Sertraline. Depression [6A70-6A7Z] [12]
Trimipramine DM1SC8M Moderate Additive CNS depression effects by the combination of Aldesleukin and Trimipramine. Depression [6A70-6A7Z] [12]
Cyclobenzaprine DM1YBRM Moderate Additive CNS depression effects by the combination of Aldesleukin and Cyclobenzaprine. Depression [6A70-6A7Z] [12]
Fluoxetine DM3PD2C Moderate Additive CNS depression effects by the combination of Aldesleukin and Fluoxetine. Depression [6A70-6A7Z] [12]
Nortriptyline DM4KDYJ Moderate Additive CNS depression effects by the combination of Aldesleukin and Nortriptyline. Depression [6A70-6A7Z] [12]
Vilazodone DM4LECQ Moderate Additive CNS depression effects by the combination of Aldesleukin and Vilazodone. Depression [6A70-6A7Z] [12]
Nefazodone DM4ZS8M Moderate Additive CNS depression effects by the combination of Aldesleukin and Nefazodone. Depression [6A70-6A7Z] [12]
Paroxetine DM5PVQE Moderate Additive CNS depression effects by the combination of Aldesleukin and Paroxetine. Depression [6A70-6A7Z] [12]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Aldesleukin and Selegiline. Depression [6A70-6A7Z] [17]
Duloxetine DM9BI7M Moderate Additive CNS depression effects by the combination of Aldesleukin and Duloxetine. Depression [6A70-6A7Z] [12]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Aldesleukin and Isocarboxazid. Depression [6A70-6A7Z] [17]
Milnacipran DMBFE74 Moderate Additive CNS depression effects by the combination of Aldesleukin and Milnacipran. Depression [6A70-6A7Z] [12]
Escitalopram DMFK9HG Moderate Additive CNS depression effects by the combination of Aldesleukin and Escitalopram. Depression [6A70-6A7Z] [12]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Aldesleukin and Tranylcypromine. Depression [6A70-6A7Z] [17]
Desvenlafaxine DMHD4PE Moderate Additive CNS depression effects by the combination of Aldesleukin and Desvenlafaxine. Depression [6A70-6A7Z] [12]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Aldesleukin and Phenelzine. Depression [6A70-6A7Z] [17]
Clomipramine DMINRKW Moderate Additive CNS depression effects by the combination of Aldesleukin and Clomipramine. Depression [6A70-6A7Z] [12]
Trazodone DMK1GBJ Moderate Additive CNS depression effects by the combination of Aldesleukin and Trazodone. Depression [6A70-6A7Z] [12]
Amitriptyline DMK7F9S Moderate Additive CNS depression effects by the combination of Aldesleukin and Amitriptyline. Depression [6A70-6A7Z] [12]
Amoxapine DMKITQE Moderate Additive CNS depression effects by the combination of Aldesleukin and Amoxapine. Depression [6A70-6A7Z] [12]
Mirtazapine DML53ZJ Moderate Additive CNS depression effects by the combination of Aldesleukin and Mirtazapine. Depression [6A70-6A7Z] [12]
Protriptyline DMNHTZI Moderate Additive CNS depression effects by the combination of Aldesleukin and Protriptyline. Depression [6A70-6A7Z] [12]
Doxepin DMPI98T Moderate Additive CNS depression effects by the combination of Aldesleukin and Doxepin. Depression [6A70-6A7Z] [12]
Maprotiline DMPWB7T Moderate Additive CNS depression effects by the combination of Aldesleukin and Maprotiline. Depression [6A70-6A7Z] [12]
Fluvoxamine DMQTJSX Moderate Additive CNS depression effects by the combination of Aldesleukin and Fluvoxamine. Depression [6A70-6A7Z] [12]
Venlafaxine DMR6QH0 Moderate Additive CNS depression effects by the combination of Aldesleukin and Venlafaxine. Depression [6A70-6A7Z] [12]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Aldesleukin and Esketamine. Depression [6A70-6A7Z] [12]
PMID27977313-Compound-29 DMIF7KG Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and PMID27977313-Compound-29. Discovery agent [N.A.] [20]
Citalopram derivative 1 DMITX1G Moderate Additive CNS depression effects by the combination of Aldesleukin and Citalopram derivative 1. Discovery agent [N.A.] [12]
Heroin diacetylmorphine DMDBWHY Moderate Additive CNS depression effects by the combination of Aldesleukin and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [13]
Meclizine DMS7T13 Moderate Additive CNS depression effects by the combination of Aldesleukin and Meclizine. Dizziness and giddiness [MB48] [12]
Diazepam DM08E9O Moderate Additive CNS depression effects by the combination of Aldesleukin and Diazepam. Epilepsy/seizure [8A61-8A6Z] [12]
Primidone DM0WX6I Moderate Additive CNS depression effects by the combination of Aldesleukin and Primidone. Epilepsy/seizure [8A61-8A6Z] [12]
Cenobamate DM8KLU9 Moderate Additive CNS depression effects by the combination of Aldesleukin and Cenobamate. Epilepsy/seizure [8A61-8A6Z] [12]
Clonazepam DMTO13J Moderate Additive CNS depression effects by the combination of Aldesleukin and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [12]
Phenobarbital DMXZOCG Moderate Additive CNS depression effects by the combination of Aldesleukin and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [12]
Cannabidiol DM0659E Moderate Additive CNS depression effects by the combination of Aldesleukin and Cannabidiol. Epileptic encephalopathy [8A62] [12]
Diphenhydramine DMKQTBA Moderate Additive CNS depression effects by the combination of Aldesleukin and Diphenhydramine. Episodic vestibular syndrome [AB31] [12]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Aldesleukin and Procarbazine. Hodgkin lymphoma [2B30] [17]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [21]
Indinavir DM0T3YH Moderate Decreased metabolism of Aldesleukin caused by Indinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [23]
Saquinavir DMG814N Moderate Decreased metabolism of Aldesleukin caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Aldesleukin caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Ritonavir DMU764S Moderate Decreased metabolism of Aldesleukin caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Aldesleukin and Mipomersen. Hyper-lipoproteinaemia [5C80] [24]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Aldesleukin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [25]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Aldesleukin and BMS-201038. Hyper-lipoproteinaemia [5C80] [26]
Temazepam DM02A65 Moderate Additive CNS depression effects by the combination of Aldesleukin and Temazepam. Insomnia [7A00-7A0Z] [12]
Suvorexant DM0E6S3 Moderate Additive CNS depression effects by the combination of Aldesleukin and Suvorexant. Insomnia [7A00-7A0Z] [12]
Amobarbital DM0GQ8N Moderate Additive CNS depression effects by the combination of Aldesleukin and Amobarbital. Insomnia [7A00-7A0Z] [12]
Ethchlorvynol DM53IP1 Moderate Additive CNS depression effects by the combination of Aldesleukin and Ethchlorvynol. Insomnia [7A00-7A0Z] [12]
Ramelteon DM7IW9J Moderate Additive CNS depression effects by the combination of Aldesleukin and Ramelteon. Insomnia [7A00-7A0Z] [12]
Eszopiclone DM8RZ9H Moderate Additive CNS depression effects by the combination of Aldesleukin and Eszopiclone. Insomnia [7A00-7A0Z] [12]
Flurazepam DMAL4G0 Moderate Additive CNS depression effects by the combination of Aldesleukin and Flurazepam. Insomnia [7A00-7A0Z] [12]
Butabarbital DMC5AST Moderate Additive CNS depression effects by the combination of Aldesleukin and Butabarbital. Insomnia [7A00-7A0Z] [12]
Triazolam DMETYK5 Moderate Additive CNS depression effects by the combination of Aldesleukin and Triazolam. Insomnia [7A00-7A0Z] [12]
Pentobarbital DMFNH7L Moderate Additive CNS depression effects by the combination of Aldesleukin and Pentobarbital. Insomnia [7A00-7A0Z] [12]
Zaleplon DMGFWSM Moderate Additive CNS depression effects by the combination of Aldesleukin and Zaleplon. Insomnia [7A00-7A0Z] [12]
Propiomazine DMKY8V1 Moderate Additive CNS depression effects by the combination of Aldesleukin and Propiomazine. Insomnia [7A00-7A0Z] [12]
Tasimelteon DMLOQ1V Moderate Additive CNS depression effects by the combination of Aldesleukin and Tasimelteon. Insomnia [7A00-7A0Z] [12]
Paraldehyde DMOC1BX Moderate Additive CNS depression effects by the combination of Aldesleukin and Paraldehyde. Insomnia [7A00-7A0Z] [12]
Nabilone DMVRYT2 Moderate Additive CNS depression effects by the combination of Aldesleukin and Nabilone. Insomnia [7A00-7A0Z] [12]
Quazepam DMY4D87 Moderate Additive CNS depression effects by the combination of Aldesleukin and Quazepam. Insomnia [7A00-7A0Z] [12]
Estazolam DMZGXUM Moderate Additive CNS depression effects by the combination of Aldesleukin and Estazolam. Insomnia [7A00-7A0Z] [12]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Aldesleukin and Polyethylene glycol. Irritable bowel syndrome [DD91] [27]
Remimazolam DMLVSYX Moderate Additive CNS depression effects by the combination of Aldesleukin and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [12]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Methotrexate. Leukaemia [2A60-2B33] [14]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Aldesleukin and Denosumab. Low bone mass disorder [FB83] [28]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Aldesleukin and Porfimer Sodium. Lung cancer [2C25] [29]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Aldesleukin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [30]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Aldesleukin caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [31]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [20]
Cladribine DM3JDRP Major Additive immunosuppressive effects by the combination of Aldesleukin and Cladribine. Mature B-cell leukaemia [2A82] [14]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Idelalisib. Mature B-cell leukaemia [2A82] [32]
Alemtuzumab DMZL3IV Moderate Additive immunosuppressive effects by the combination of Aldesleukin and Alemtuzumab. Mature B-cell leukaemia [2A82] [33]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Clofarabine. Mature B-cell lymphoma [2A85] [34]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Aldesleukin and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [35]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Aldesleukin caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [36]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Aldesleukin and Lasmiditan. Migraine [8A80] [37]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Aldesleukin and Flibanserin. Mood disorder [6A60-6E23] [12]
Dexmedetomidine DM93L4X Moderate Additive CNS depression effects by the combination of Aldesleukin and Dexmedetomidine. Mood/affect symptom [MB24] [12]
Midazolam DMXOELT Moderate Additive CNS depression effects by the combination of Aldesleukin and Midazolam. Mood/affect symptom [MB24] [12]
Doxylamine DMKOXFE Moderate Additive CNS depression effects by the combination of Aldesleukin and Doxylamine. Morning sickness disorder [SC00] [12]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Aldesleukin and Thalidomide. Multiple myeloma [2A83] [38]
Baclofen DM0QV1J Moderate Additive CNS depression effects by the combination of Aldesleukin and Baclofen. Multiple sclerosis [8A40] [12]
Interferon beta-1a DM1A6RV Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Interferon beta-1a. Multiple sclerosis [8A40] [39]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Aldesleukin and Siponimod. Multiple sclerosis [8A40] [10]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Aldesleukin and Fingolimod. Multiple sclerosis [8A40] [40]
Interferon beta-1b DMCN61Z Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Interferon beta-1b. Multiple sclerosis [8A40] [39]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Aldesleukin and Ozanimod. Multiple sclerosis [8A40] [17]
Carisoprodol DMWR1JC Moderate Additive CNS depression effects by the combination of Aldesleukin and Carisoprodol. Musculoskeletal disorder [FA00-FC0Z] [12]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Aldesleukin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [41]
Droperidol DM0DXA8 Moderate Additive CNS depression effects by the combination of Aldesleukin and Droperidol. Nausea/vomiting [MD90] [12]
Prochlorperazine DM53SRA Moderate Additive CNS depression effects by the combination of Aldesleukin and Prochlorperazine. Nausea/vomiting [MD90] [12]
Promethazine DM6I5GR Moderate Additive CNS depression effects by the combination of Aldesleukin and Promethazine. Nausea/vomiting [MD90] [12]
Cyclizine DM9G7BS Moderate Additive CNS depression effects by the combination of Aldesleukin and Cyclizine. Nausea/vomiting [MD90] [12]
Thiethylperazine DMU3IET Moderate Additive CNS depression effects by the combination of Aldesleukin and Thiethylperazine. Nausea/vomiting [MD90] [12]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Aldesleukin and Bupropion. Nicotine use disorder [6C4A] [42]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Aldesleukin and Levomethadyl Acetate. Opioid use disorder [6C43] [13]
Pentazocine DM1XBHS Moderate Additive CNS depression effects by the combination of Aldesleukin and Pentazocine. Pain [MG30-MG3Z] [12]
Dextropropoxyphene DM23HCX Moderate Additive CNS depression effects by the combination of Aldesleukin and Dextropropoxyphene. Pain [MG30-MG3Z] [13]
Butorphanol DM5KYPJ Moderate Additive CNS depression effects by the combination of Aldesleukin and Butorphanol. Pain [MG30-MG3Z] [12]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Aldesleukin and Oxymorphone. Pain [MG30-MG3Z] [12]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Aldesleukin and Levorphanol. Pain [MG30-MG3Z] [12]
Hydromorphone DMHP21E Moderate Additive CNS depression effects by the combination of Aldesleukin and Hydromorphone. Pain [MG30-MG3Z] [12]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Aldesleukin and Dezocine. Pain [MG30-MG3Z] [12]
Codeine DMJX6ZG Moderate Additive CNS depression effects by the combination of Aldesleukin and Codeine. Pain [MG30-MG3Z] [12]
Nalbuphine DMOSQGU Moderate Additive CNS depression effects by the combination of Aldesleukin and Nalbuphine. Pain [MG30-MG3Z] [12]
Buprenorphine DMPRI8G Moderate Additive CNS depression effects by the combination of Aldesleukin and Buprenorphine. Pain [MG30-MG3Z] [12]
Hydrocodone DMQ2JO5 Moderate Additive CNS depression effects by the combination of Aldesleukin and Hydrocodone. Pain [MG30-MG3Z] [12]
Tramadol DMRQD04 Major Increased risk of lowers seizure threshold by the combination of Aldesleukin and Tramadol. Pain [MG30-MG3Z] [43]
Meperidine DMX4GND Moderate Additive CNS depression effects by the combination of Aldesleukin and Meperidine. Pain [MG30-MG3Z] [12]
Oxycodone DMXLKHV Moderate Additive CNS depression effects by the combination of Aldesleukin and Oxycodone. Pain [MG30-MG3Z] [12]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Aldesleukin and Safinamide. Parkinsonism [8A00] [17]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Aldesleukin and Rasagiline. Parkinsonism [8A00] [17]
Orphenadrine DMW542E Moderate Additive CNS depression effects by the combination of Aldesleukin and Orphenadrine. Parkinsonism [8A00] [12]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Aldesleukin and Lindane. Pediculosis [1G00] [44]
Efalizumab DMCKL5V Moderate Additive immunosuppressive effects by the combination of Aldesleukin and Efalizumab. Psoriasis [EA90] [45]
Infliximab DMH7OIA Major Additive immunosuppressive effects by the combination of Aldesleukin and Infliximab. Psoriasis [EA90] [46]
Levomepromazine DMIKFEL Moderate Additive CNS depression effects by the combination of Aldesleukin and Levomepromazine. Psychotic disorder [6A20-6A25] [12]
Triflupromazine DMKFQJP Moderate Additive CNS depression effects by the combination of Aldesleukin and Triflupromazine. Psychotic disorder [6A20-6A25] [12]
Gatifloxacin DMSL679 Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [16]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Aldesleukin and Canakinumab. Rheumatoid arthritis [FA20] [47]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Aldesleukin and Rilonacept. Rheumatoid arthritis [FA20] [47]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Aldesleukin and Golimumab. Rheumatoid arthritis [FA20] [46]
Adalimumab DMQMV1B Major Additive immunosuppressive effects by the combination of Aldesleukin and Adalimumab. Rheumatoid arthritis [FA20] [46]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Aldesleukin and Leflunomide. Rheumatoid arthritis [FA20] [25]
Mesoridazine DM2ZGAN Moderate Additive CNS depression effects by the combination of Aldesleukin and Mesoridazine. Schizophrenia [6A20] [12]
Thioridazine DM35M8J Moderate Additive CNS depression effects by the combination of Aldesleukin and Thioridazine. Schizophrenia [6A20] [12]
Iloperidone DM6AUFY Moderate Additive CNS depression effects by the combination of Aldesleukin and Iloperidone. Schizophrenia [6A20] [12]
Paliperidone DM7NPJS Moderate Additive CNS depression effects by the combination of Aldesleukin and Paliperidone. Schizophrenia [6A20] [12]
Haloperidol DM96SE0 Moderate Additive CNS depression effects by the combination of Aldesleukin and Haloperidol. Schizophrenia [6A20] [12]
Perphenazine DMA4MRX Moderate Additive CNS depression effects by the combination of Aldesleukin and Perphenazine. Schizophrenia [6A20] [12]
Chlorpromazine DMBGZI3 Moderate Additive CNS depression effects by the combination of Aldesleukin and Chlorpromazine. Schizophrenia [6A20] [12]
Thiothixene DMDINC4 Moderate Additive CNS depression effects by the combination of Aldesleukin and Thiothixene. Schizophrenia [6A20] [12]
Trifluoperazine DMKBYWI Moderate Additive CNS depression effects by the combination of Aldesleukin and Trifluoperazine. Schizophrenia [6A20] [12]
Risperidone DMN6DXL Moderate Additive CNS depression effects by the combination of Aldesleukin and Risperidone. Schizophrenia [6A20] [12]
Fentanyl DM8WAHT Moderate Additive CNS depression effects by the combination of Aldesleukin and Fentanyl. Sensation disturbance [MB40] [12]
Sufentanil DMU7YEL Moderate Additive CNS depression effects by the combination of Aldesleukin and Sufentanil. Sensation disturbance [MB40] [12]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Aldesleukin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [48]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [14]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Aldesleukin and Naltrexone. Substance abuse [6C40] [49]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Aldesleukin and Azathioprine. Transplant rejection [NE84] [10]
Cinoxacin DM4EWNS Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [16]
Nalidixic acid DMRM0JV Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [16]
Enoxacin DMYTE6L Minor Decreased absorption of Aldesleukin due to intestinal mucosa variation caused by Enoxacin. Urinary tract infection [GC08] [16]
Methdilazine DMAUHQX Moderate Additive CNS depression effects by the combination of Aldesleukin and Methdilazine. Vasomotor/allergic rhinitis [CA08] [12]
Trimeprazine DMEMV9D Moderate Additive CNS depression effects by the combination of Aldesleukin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [13]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Aldesleukin and Cetirizine. Vasomotor/allergic rhinitis [CA08] [12]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Aldesleukin and Ganciclovir. Virus infection [1A24-1D9Z] [10]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Aldesleukin and Valganciclovir. Virus infection [1A24-1D9Z] [10]
⏷ Show the Full List of 197 DDI Information of This Drug

References

1 Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs. 1993 Sep;46(3):446-514.
2 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3 Aldesleukin. 2018 May 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012C.
4 Targeting interleukin-1 and inflammation in lung cancer. Biomark Res. 2022 Jan 27;10(1):5.
5 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
6 Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res. 2008 Jul 1;14(13):4192-9.
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
10 Cerner Multum, Inc. "Australian Product Information.".
11 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
12 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
13 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
14 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
16 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
17 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
18 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
19 Product Information. Vistide (cidofovir). Gilead Sciences, Foster City, CA.
20 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
21 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
22 Piscitelli SC, Vogel S, Figg WD, et al. "Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus." Pharmacotherapy 18 (1998): 1212-6. [PMID: 9855318]
23 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
24 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
25 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
26 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
27 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
28 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
29 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
30 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
31 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
32 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
33 Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.
34 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
35 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
36 Canadian Pharmacists Association.
37 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
38 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
39 Product Information. Avonex (interferon beta-1a). Biogen, Cambridge, MA.
40 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
41 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
42 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
43 Product Information. Ultram (tramadol). McNeil Pharmaceutical, Raritan, NJ.
44 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
45 Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA.
46 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
47 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
48 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
49 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.